Medical News / ESC 2022 - SGLT2 Inhibitor Therapy Foundational in Wide Range of Heart Failure Management

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
AHA 2023: Disparities for Time to HCM Diagnosis in Contemporary Care, with Ahmad Masri, MD, MS
New research into the speed of diagnosis of hypertrophic cardiomyopathy in the United States is providing ... read more
Newly reported from AHA 2023: AI App Predicts Heart Failure Early by Listening to People Talk
In a recent study, a smartphone app using artificial intelligence (AI) predicted heart failure 3 weeks ... read more
Newscasting from AHA 2023: Cutting Sodium in Diet Significantly Lowers Blood Pressure in One Week
Reducing sodium in diet to 4,000 mg/day significantly lowers blood pressure after 1 week, a new ... read more
From AHA 2023: Sotagliflozin (INPEFA®) is Associated with Improving Heart Failure, Atherosclerotic Events
On November 12, 2023, Lexicon Pharmaceuticals, Inc. announced a post hoc analysis of clinical data from ... read more